Published in J Virol on October 01, 2004
Analysis of the functions of herpes simplex virus type 1 regulatory protein ICP0 that are critical for lytic infection and derepression of quiescent viral genomes. J Virol (2009) 1.48
Live covisualization of competing adeno-associated virus and herpes simplex virus type 1 DNA replication: molecular mechanisms of interaction. J Virol (2007) 0.90
Definition of herpes simplex virus type 1 helper activities for adeno-associated virus early replication events. PLoS Pathog (2009) 0.89
Does human bocavirus infection depend on helper viruses? A challenging case report. Virol J (2011) 0.85
Identification of rep-associated factors in herpes simplex virus type 1-induced adeno-associated virus type 2 replication compartments. J Virol (2010) 0.83
Four-dimensional visualization of the simultaneous activity of alternative adeno-associated virus replication origins. J Virol (2005) 0.82
Inhibition of herpes simplex virus type 1 replication by adeno-associated virus rep proteins depends on their combined DNA-binding and ATPase/helicase activities. J Virol (2010) 0.81
Promyelocytic leukemia protein is a cell-intrinsic factor inhibiting parvovirus DNA replication. J Virol (2013) 0.81
Impact of the MRN Complex on Adeno-Associated Virus Integration and Replication during Coinfection with Herpes Simplex Virus 1. J Virol (2015) 0.75
Herpes simplex virus type 1/adeno-associated virus hybrid vectors. Open Virol J (2010) 0.75
A herpes simplex virus type 1 function continuously required for early and late virus RNA synthesis. Nature (1980) 8.47
Transcriptional repression by YY1, a human GLI-Krüppel-related protein, and relief of repression by adenovirus E1A protein. Cell (1991) 8.31
Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol (1985) 8.12
Isolation and characterization of a herpes simplex virus type 1 mutant containing a deletion within the gene encoding the immediate early polypeptide Vmw110. J Gen Virol (1986) 6.74
Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J Virol (1989) 5.77
Deletion mutants in the gene encoding the herpes simplex virus type 1 immediate-early protein ICP0 exhibit impaired growth in cell culture. J Virol (1987) 5.71
Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J Virol (1980) 5.09
HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J (1994) 4.61
The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J Virol (1998) 4.43
Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A (2000) 4.39
Manipulation of adenovirus vectors. Methods Mol Biol (1991) 4.31
Herpes simplex virus 1 alpha regulatory protein ICP0 interacts with and stabilizes the cell cycle regulator cyclin D3. J Virol (1997) 4.26
Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro. J Virol (2002) 4.06
Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication. J Virol (1981) 3.72
Factors that bind to adeno-associated virus terminal repeats. J Virol (1989) 3.56
Replication of adeno-associated virus in synchronized cells without the addition of a helper virus. J Virol (1987) 3.44
The herpes simplex virus type 1 regulatory protein ICP0 enhances virus replication during acute infection and reactivation from latency. J Virol (1993) 3.43
A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J (1997) 3.34
Re-SET-ting heterochromatin by histone methyltransferases. Trends Cell Biol (2001) 3.16
ICP0, a regulator of herpes simplex virus during lytic and latent infection. Bioessays (2000) 3.09
Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem (1993) 3.02
Construction and characterization of herpes simplex virus type 1 mutants with defined lesions in immediate early gene 1. J Gen Virol (1989) 2.97
Herpes simplex virus type 1 immediate-early protein vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. J Virol (1999) 2.93
Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection. J Virol (1989) 2.91
Latent infection of KB cells with adeno-associated virus type 2. J Virol (1986) 2.88
Interaction of herpes simplex virus 1 alpha regulatory protein ICP0 with elongation factor 1delta: ICP0 affects translational machinery. J Virol (1997) 2.87
An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. J Virol (1995) 2.82
Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110. EMBO J (1999) 2.79
Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology (1975) 2.77
Herpes simplex virus type 1 immediate-early protein Vmw110 reactivates latent herpes simplex virus type 2 in an in vitro latency system. J Virol (1989) 2.76
DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene (2001) 2.57
Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene (2001) 2.52
Analysis of the functional domains of herpes simplex virus type 1 immediate-early polypeptide Vmw110. J Mol Biol (1988) 2.46
Biology of adeno-associated virus. Curr Top Microbiol Immunol (1996) 2.40
DNA amplification of adeno-associated virus as a response to cellular genotoxic stress. Cancer Res (1988) 2.39
Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J Virol (2003) 2.33
Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene (2001) 2.33
Subcellular compartmentalization of adeno-associated virus type 2 assembly. J Virol (1997) 2.31
A cellular function can enhance gene expression and plating efficiency of a mutant defective in the gene for ICP0, a transactivating protein of herpes simplex virus type 1. J Virol (1991) 2.25
ICP4, the major transcriptional regulatory protein of herpes simplex virus type 1, forms a tripartite complex with TATA-binding protein and TFIIB. J Virol (1993) 2.16
The degradation of promyelocytic leukemia and Sp100 proteins by herpes simplex virus 1 is mediated by the ubiquitin-conjugating enzyme UbcH5a. Proc Natl Acad Sci U S A (2003) 2.12
Degradation of nucleosome-associated centromeric histone H3-like protein CENP-A induced by herpes simplex virus type 1 protein ICP0. J Biol Chem (2000) 2.10
A viral activator of gene expression functions via the ubiquitin-proteasome pathway. EMBO J (1998) 2.06
Adeno-associated virus P5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor. J Virol (1989) 1.96
Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol (1999) 1.95
The infected cell protein 0 of herpes simplex virus 1 dynamically interacts with proteasomes, binds and activates the cdc34 E2 ubiquitin-conjugating enzyme, and possesses in vitro E3 ubiquitin ligase activity. Proc Natl Acad Sci U S A (2001) 1.94
The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J Virol (1997) 1.89
Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins. J Virol (1995) 1.86
Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. J Virol (1999) 1.84
Herpes simplex virus 1-infected cell protein 0 contains two E3 ubiquitin ligase sites specific for different E2 ubiquitin-conjugating enzymes. Proc Natl Acad Sci U S A (2002) 1.82
Replication of herpes simplex virus DNA. J Biol Chem (1999) 1.77
ICP0, ICP4, or VP16 expressed from adenovirus vectors induces reactivation of latent herpes simplex virus type 1 in primary cultures of latently infected trigeminal ganglion cells. J Virol (2001) 1.76
Activation of gene expression by herpes simplex virus type 1 ICP0 occurs at the level of mRNA synthesis. J Virol (1997) 1.72
Mutational analysis of adeno-associated virus Rep protein-mediated inhibition of heterologous and homologous promoters. J Virol (1995) 1.71
Overexpression of promyelocytic leukemia protein precludes the dispersal of ND10 structures and has no effect on accumulation of infectious herpes simplex virus 1 or its proteins. J Virol (2002) 1.67
Replication of adeno-associated virus in cells irradiated with UV light at 254 nm. J Virol (1989) 1.67
Herpes simplex virus type 1 immediate-early protein Vmw110 inhibits progression of cells through mitosis and from G(1) into S phase of the cell cycle. J Virol (1999) 1.66
Negative regulation of the adeno-associated virus (AAV) P5 promoter involves both the P5 rep binding site and the consensus ATP-binding motif of the AAV Rep68 protein. J Virol (1995) 1.63
The herpes simplex virus type 1 (HSV-1) regulatory protein ICP0 interacts with and Ubiquitinates p53. J Biol Chem (2003) 1.58
A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J Virol (1991) 1.56
Interaction of the viral activator protein ICP4 with TFIID through TAF250. Mol Cell Biol (1996) 1.56
Adenovirus E1A proteins interact with the cellular YY1 transcription factor. J Virol (1995) 1.52
Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels. J Virol (1994) 1.48
Herpes simplex virus 1 alpha regulatory protein ICP0 functionally interacts with cellular transcription factor BMAL1. Proc Natl Acad Sci U S A (2001) 1.46
Modification of some biological properties of HeLa cells containing adeno-associated virus DNA integrated into chromosome 17. J Virol (1992) 1.45
The adenovirus DNA-binding protein stimulates the rate of transcription directed by adenovirus and adeno-associated virus promoters. J Virol (1990) 1.39
The cellular transcription factor SP1 and an unknown cellular protein are required to mediate Rep protein activation of the adeno-associated virus p19 promoter. J Virol (1997) 1.34
The adeno-associated virus type 2 p40 promoter requires a proximal Sp1 interaction and a p19 CArG-like element to facilitate Rep transactivation. J Virol (1997) 1.34
Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J Virol (2000) 1.32
Efficient activation of viral genomes by levels of herpes simplex virus ICP0 insufficient to affect cellular gene expression or cell survival. J Virol (2001) 1.17
The Rep protein of adeno-associated virus type 2 interacts with single-stranded DNA-binding proteins that enhance viral replication. J Virol (2004) 1.17
Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc Natl Acad Sci U S A (2000) 1.13
Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci U S A (1996) 1.12
Cloning, sequencing, and functional characterization of the two subunits of the pseudorabies virus DNA polymerase holoenzyme: evidence for specificity of interaction. J Virol (1995) 1.05
Rep-dependent initiation of adeno-associated virus type 2 DNA replication by a herpes simplex virus type 1 replication complex in a reconstituted system. J Virol (2001) 1.05
Adeno-associated virus DNA replication complexes in herpes simplex virus or adenovirus-infected cells. J Biol Chem (1979) 1.04
Characterization of the novel E3 ubiquitin ligase encoded in exon 3 of herpes simplex virus-1-infected cell protein 0. Proc Natl Acad Sci U S A (2002) 1.03
Chromatin-like structure of adeno-associated virus DNA in infected cells. J Virol (1983) 1.03
Detection of adeno-associated virus type 2 in human peripheral blood cells. J Gen Virol (1992) 0.98
Spatial and temporal organization of adeno-associated virus DNA replication in live cells. J Virol (2004) 0.96
Adeno-associated virus type 2: a latent life cycle. Prog Nucleic Acid Res Mol Biol (1994) 0.94
Herpes simplex virus 1 mutant in which the ICP0 HUL-1 E3 ubiquitin ligase site is disrupted stabilizes cdc34 but degrades D-type cyclins and exhibits diminished neurotoxicity. J Virol (2003) 0.93
Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther (2009) 3.33
Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther (2008) 1.63
Functional interaction between class II histone deacetylases and ICP0 of herpes simplex virus type 1. J Virol (2004) 1.59
Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther (2010) 1.51
Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol (2008) 1.44
Subretinal delivery of recombinant AAV serotype 8 vector in dogs results in gene transfer to neurons in the brain. Mol Ther (2008) 1.41
Gene therapy of the brain in the dog model of Hurler's syndrome. Ann Neurol (2006) 1.32
Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med (2014) 1.32
A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther (2011) 1.29
Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther (2006) 1.24
In vivo gene regulation using tetracycline-regulatable systems. Adv Drug Deliv Rev (2009) 1.23
Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther (2010) 1.23
Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol Ther (2009) 1.21
Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates. Mol Ther (2008) 1.20
Autoimmune anemia in macaques following erythropoietin gene therapy. Blood (2004) 1.16
Determination of minimum herpes simplex virus type 1 components necessary to localize transcriptionally active DNA to ND10. J Virol (2003) 1.15
A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5. Mol Ther (2002) 1.14
Helper functions required for wild type and recombinant adeno-associated virus growth. Curr Gene Ther (2005) 1.14
Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol Ther (2005) 1.10
N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers. J Neurochem (2010) 1.10
Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle. Mol Ther (2004) 1.09
Nucleolin is required for an efficient herpes simplex virus type 1 infection. J Virol (2008) 1.07
Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol Ther (2005) 1.07
Human alpha-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution. Hum Gene Ther (2009) 1.06
Postsurgical assessment and long-term safety of recombinant adeno-associated virus-mediated gene transfer into the retinas of dogs and primates. Arch Ophthalmol (2005) 1.02
Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Hum Mol Genet (2010) 1.01
Restoration of vision in the pde6β-deficient dog, a large animal model of rod-cone dystrophy. Mol Ther (2012) 1.00
International efforts for recombinant adeno-associated viral vector reference standards. Mol Ther (2008) 1.00
Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J Virol (2012) 0.99
Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther (2012) 0.98
The cellular TATA binding protein is required for rep-dependent replication of a minimal adeno-associated virus type 2 p5 element. J Virol (2005) 0.98
scAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease. Hum Gene Ther (2013) 0.98
Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors. J Immunol (2012) 0.98
Nucleolin interacts with US11 protein of herpes simplex virus 1 and is involved in its trafficking. J Virol (2011) 0.94
Five recombinant simian immunodeficiency virus pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat. Mol Ther (2002) 0.93
The RPGRIP1-deficient dog, a promising canine model for gene therapy. Mol Vis (2009) 0.92
"Genetic Doping" with erythropoietin cDNA in primate muscle is detectable. Mol Ther (2004) 0.92
Immune responses to gene product of inducible promoters. Curr Gene Ther (2007) 0.92
Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material. Hum Gene Ther (2014) 0.91
Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer. Front Microbiol (2011) 0.91
Superiority of bone marrow-derived dendritic cells over monocyte-derived ones for the expansion of regulatory T cells in the macaque. Transplantation (2008) 0.90
Definition of herpes simplex virus type 1 helper activities for adeno-associated virus early replication events. PLoS Pathog (2009) 0.89
The structures of bovine herpesvirus 1 virion and concatemeric DNA: implications for cleavage and packaging of herpesvirus genomes. Virology (2003) 0.88
Infection with herpes simplex type 1-based amplicon vectors results in an IRF3/7-dependent, TLR-independent activation of the innate antiviral response in primary human fibroblasts. J Gen Virol (2009) 0.87
Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines. J Infect Dis (2012) 0.87
Cytotoxic immune response blunts long-term transgene expression after efficient retroviral-mediated hepatic gene transfer in rat. Mol Ther (2002) 0.87
Novel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors. J Gene Med (2010) 0.87
Sustained tetracycline-regulated transgene expression in vivo in rat retinal ganglion cells using a single type 2 adeno-associated viral vector. J Gene Med (2003) 0.86
Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes. Hum Gene Ther (2003) 0.85
Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity. J Gen Virol (2005) 0.84
Improving rAAV production and purification: towards the definition of a scaleable process. J Gene Med (2004) 0.84
Identification of replication-competent HSV-1 Cgal+ strain signaling targets in human hepatoma cells by functional organelle proteomics. Mol Cell Proteomics (2008) 0.84
Early detection of a two-long-terminal-repeat junction molecule in the cytoplasm of recombinant murine leukemia virus-infected cells. J Virol (2004) 0.84
Hepatitis B virus infection enhances susceptibility toward adeno-associated viral vector transduction in vitro and in vivo. Hepatology (2014) 0.83
Phenotypic rescue after adeno-associated virus-mediated delivery of 4-sulfatase to the retinal pigment epithelium of feline mucopolysaccharidosis VI. J Gene Med (2002) 0.83
Identification of rep-associated factors in herpes simplex virus type 1-induced adeno-associated virus type 2 replication compartments. J Virol (2010) 0.83
Characterization of producer cell-dependent restriction of murine leukemia virus replication. J Virol (2002) 0.82
Gene therapeutic prospects in early onset of severe retinal dystrophy: restoration of vision in RPE65 Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Bull Mem Acad R Med Belg (2006) 0.82
HSV-1 Cgal+ infection promotes quaking RNA binding protein production and induces nuclear-cytoplasmic shuttling of quaking I-5 isoform in human hepatoma cells. Mol Cell Proteomics (2011) 0.82
Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer. Liver Int (2011) 0.82
Adeno-associated viral vector-mediated transgene expression is independent of DNA methylation in primate liver and skeletal muscle. PLoS One (2011) 0.82
Inhibition of herpes simplex virus type 1 replication by adeno-associated virus rep proteins depends on their combined DNA-binding and ATPase/helicase activities. J Virol (2010) 0.81
HSV-1 amplicon vectors: a promising and versatile tool for gene delivery. Expert Opin Biol Ther (2007) 0.81
HSV as a vector in vaccine development and gene therapy. Hum Vaccin (2008) 0.81
HSV-1 amplicon vectors launch the production of heterologous rotavirus-like particles and induce rotavirus-specific immune responses in mice. Mol Ther (2012) 0.81
Characterization of antiproliferative and cytotoxic properties of the HSV-1 immediate-early ICPo protein. J Gene Med (2005) 0.81
Adeno-associated virus type 2 modulates the host DNA damage response induced by herpes simplex virus 1 during coinfection. J Virol (2011) 0.81
Identification of replication-competent HSV-1 Cgal+ strain targets in a mouse model of human hepatocarcinoma xenograft. J Proteomics (2009) 0.80
Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines. J Gene Med (2004) 0.80
HSV as a vector in vaccine development and gene therapy. Adv Exp Med Biol (2009) 0.80
Regulation of retinal function but nonrescue of vision in RPE65-deficient dogs treated with doxycycline-regulatable AAV vectors. Mol Ther (2010) 0.80
PCR-based detection of gene transfer vectors: application to gene doping surveillance. Anal Bioanal Chem (2013) 0.80
Efficient intrathymic gene transfer following in situ administration of a rAAV serotype 8 vector in mice and nonhuman primates. Mol Ther (2008) 0.80
Development and utility of an internal threshold control (ITC) real-time PCR assay for exogenous DNA detection. PLoS One (2012) 0.80
Intracellular route and biological activity of exogenously delivered Rep proteins from the adeno-associated virus type 2. Virology (2005) 0.79
Failure of lower motor neuron radial outgrowth precedes retrograde degeneration in a feline model of spinal muscular atrophy. J Comp Neurol (2012) 0.79
Neonatal systemic delivery of scAAV9 in rodents and large animals results in gene transfer to RPE cells in the retina. Exp Eye Res (2011) 0.79
Adeno-associated virus capsid serotype identification: Analytical methods development and application. J Virol Methods (2009) 0.79
Amplicon vectors as outstanding tools to study and modify cognitive functions. Curr Gene Ther (2006) 0.79
Factors influencing immune response after in vivo retrovirus-mediated gene transfer to the liver. J Gene Med (2004) 0.78
Herpes simplex virus type 1-derived recombinant and amplicon vectors. Methods Mol Biol (2011) 0.78
Immunological tolerance to muscle autoantigens involves peripheral deletion of autoreactive CD8+ T cells. PLoS One (2012) 0.78
Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1. J Virol (2004) 0.77